644 results on '"Masaaki Yamamoto"'
Search Results
2. Validity test of small cell lung cancer (SCLC) graded prognostic assessment and proposal of a new index for patients with brain metastases from SCLC
- Author
-
Masaaki Yamamoto, Toru Serizawa, Yasunori Sato, Yoshinori Higuchi, Yasuhito Kikuchi, and Sonomi Sato
- Subjects
Brain metastases ,Small cell lung cancer ,Radiosurgery ,Prognostic grade ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and purpose: We performed a validity test of a recently-reported, small cell lung cancer (SCLC) graded prognostic assessment (GPA) system for SCLC patients with brain metastases (BMs). Thereafter, we created a new prognostic index, the SCLC Grade, for such patients. Materials and methods: We studied 508 SCLC patients selected from among nearly 7000 consecutive patients undergoing gamma knife SRS for BMs since 1998. Results: In the SCLC GPA, there were no median survival time (MST) differences among pairs of the neighboring subgroups. Therefore, the 508 patients were randomly divided into the two series, i.e., a test (340 patients) and a validity (168) series. In the test series, five factors were identified by univariable analyses as favoring longer survival (rounded lower 95 % CI of the HR was at least 1.3): Sex, Karnofsky Performance Status, tumor numbers, primary tumor status and extracerebral metastases. This new index is the sum of scores (0 and 1) of these five factors: SCLC-Grade 4–6 (score of 4, 5 or 6), 2–3 (2 or 3), and 0–1 (0 or 1). This new system showed highly statistically significant MST differences among subclasses. Next, this SCLC-Grade was applied to the verification series. Consistent results were obtained, i.e., there were highly statistically significant MST differences among subclasses. Conclusions: Our validity test results for the SCLC GPA demonstrated this system to not precisely reflect the outcomes of SCLC patients with BMs. Our results suggest the herein-proposed SCLC-Grade to have superior prognostic value.
- Published
- 2024
- Full Text
- View/download PDF
3. Composite paraganglioma-ganglioneuroma with atypical catecholamine profile and phenylethanolamine N-methyltransferase expression: a case report and literature review
- Author
-
Yuriko Sasaki, Maki Kanzawa, Masaaki Yamamoto, Keitaro Kanie, Hironori Bando, Kei Yoshino, Yushi Hirota, Katsumi Shigemura, Masato Fujisawa, Wataru Ogawa, and Hidenori Fukuoka
- Subjects
composite tumors ,phenylethanolamine n-methyltransferase ,pheochromocytomas and paragangliomas ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that secrete catecholamines and arise from the adrenal medulla or extra-adrenal sympathetic ganglia. These tumors secrete adrenaline and noradrenaline, but paragangliomas usually produce only noradrenaline because of the lack of phenylethanolamine N-methyltransferase (PNMT) expression. Composite paragangliomas, which are complex tumors consisting of multiple types of neuroblastic cells, are extremely rare. We present the case of a 46-year-old woman with an atypical catecholamine profile who was preoperatively diagnosed with pheochromocytoma. However, postoperative pathology revealed that the patient had an extra-adrenal paraganglioma accompanied by a ganglioneuroma, which led to the diagnosis of a composite tumor. Interestingly, PNMT is expressed in both paragangliomas and ganglioneuromas. In addition, we reviewed reported composite paragangliomas and compared their clinical features with those of composite pheochromocytomas. We also discuss various aspects of the etiology of composite paragangliomas and the mechanism by which PNMT is expressed in tumors.
- Published
- 2023
- Full Text
- View/download PDF
4. Early detection of brain metastases and appropriate local therapy followed by systemic chemotherapy may improve the prognosis of gastric cancer
- Author
-
Yasunobu Ishizuka, Takeshi Omori, Naoki Shinno, Masaaki Yamamoto, Hisashi Hara, Tomoyuki Otsuka, Minako Nishio, Naohiro Nishida, Fumie Fujisawa, Naotoshi Sugimoto, Toshinari Yagi, Masahiro Goto, Hiroki Nishikawa, and Toshihiro Kudo
- Subjects
Medicine ,Science - Abstract
Abstract Brain metastases develop in 0.5–0.7% of patients with gastric/gastroesophageal junction (G/GEJ) cancer. Although rare, brain metastasis is often identified when the patient is already symptomatic; hence prognosis is poor. Given the therapeutic developments for G/GEJ cancer, overall survival is prolonged, thereby the incidence of brain metastases is predicted to increase. We retrospectively surveyed the rate of brain metastasis among 1257 patients diagnosed with G/GEJ cancer who received chemotherapy between January 2011 and April 2021. We investigated the time of onset of brain metastasis, treatments administered, and impact of the metastasis on the overall treatment course and prognosis. Of the 741 patients included in the analysis, brain metastasis was confirmed in 16 (2.2%). The median survival time (MST) from G/GEJ cancer diagnosis was 14.9 months in patients with brain metastasis detected during the treatment period, and the MST from the diagnosis of brain metastasis was 2.8 months. Patients who received chemotherapy exhibited prolonged survival compared with those who did not (12.4 months vs 1.0 months, p
- Published
- 2023
- Full Text
- View/download PDF
5. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis
- Author
-
Wataru Ogawa, Masaaki Yamamoto, Naoki Yamamoto, Hironori Bando, Shin Urai, Yuma Motomura, Yuriko Sasaki, Yuka Ohmachi, Masaki Kobatake, Yasutaka Tsujimoto, Yuka Oi-Yo, Masaki Suzuki, Michiko Takahashi, Hidenori Fukuoka, and Genzo Iguchi
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Immune checkpoint inhibitor (ICI)-related hypophysitis (RH) is a common immune-related adverse event. The early detection of ICI-RH prevents life-threatening adrenal insufficiency. However, good predictors of secondary adrenal insufficiency in ICI-RH have not yet been reported. We hypothesized that fluctuations in plasma adrenocorticotropic hormone (ACTH) and cortisol levels occur similarly to those in thyroid-stimulating hormone and thyroid hormone (thyroxine and triiodothyronine) levels in ICI-related thyroiditis. Here, we sought to test this hypothesis. Patients who used ICI and had a history of measurement of plasma ACTH and serum cortisol concentrations were retrieved from electronic medical records, and those with a history of glucocorticoid use were excluded from the analysis. We evaluated fluctuations in plasma ACTH and serum cortisol concentrations and the development of ICI-RH. For patients with ICI-RH, data at three points (before ICI administration (pre), maximum ACTH concentration (peak), and onset of ICI-RH) were analyzed to evaluate hormone fluctuations. A total of 202 patients were retrieved from the medical record. Forty-three patients were diagnosed with ICI-RH. Twenty-six out of 43 patients had sufficient data to evaluate fluctuations in plasma ACTH and serum cortisol concentrations and no history of glucocorticoid use. ACTH concentrations changed from 37.4 (29.9–48.3) (pre) to 64.4 (46.5–106.2) (peak) pg/mL (1.72–fold increase, p=0.0026) in the patients with ICI-RH before the onset. There were no differences in cortisol concentrations between the pre and peak values in patients with ICI-RH. We also evaluated the fluctuations in plasma ACTH and serum cortisol levels in patients who did not receive ICI-RH (62 cases). However, elevation of plasma ACTH levels was not observed in patients without ICI-RH, suggesting that transient elevation of plasma ACTH levels is a unique phenomenon in patients with ICI-RH. In conclusion, plasma ACTH levels were transiently elevated in some patients with ICI-RH before the onset of secondary adrenal insufficiency. Monitoring the ACTH levels and their fluctuations may help predict the onset of ICI-RH.
- Published
- 2024
- Full Text
- View/download PDF
6. Long‐term changes in bone mineral density in postoperative patients with esophageal cancer
- Author
-
Takahito Sugase, Keijiro Sugimura, Takashi Kanemura, Tomohira Takeoka, Masaaki Yamamoto, Naoki Shinno, Hisashi Hara, Takeshi Omori, Masayoshi Yasui, and Hiroshi Miyata
- Subjects
bone mineral density ,esophageal cancer ,esophagectomy ,osteoporosis ,weight loss ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Aim The aim of this study was to investigate long‐term changes in bone mineral density (BMD) after esophagectomy, identify the risk factors for postoperative osteoporosis in patients with esophageal cancer and survival outcomes related to osteoporosis. Methods We retrospectively evaluated BMD changes for 197 consecutive patients with thoracic esophageal cancer who were disease‐free for 5 years after radical esophagectomy. Osteoporosis was diagnosed using computed tomography with an L1 attenuation threshold of ≤110 HU. Survival analysis was performed on 381 consecutive patients with 5‐year follow‐up after radical esophagectomy. Results BMD decreased annually after esophagectomy. The median attenuation (HU) was 134.2 before surgery and 135.2, 127.4, 123.3, 115.2, 105.6, and 102.4 at 6 months and 1, 2, 3, 4, and 5 years after surgery, respectively. Osteoporosis was diagnosed in 25.9% patients before surgery and 23.3%, 29.4%, 40.1%, 46.7%, 54.8%, and 60.4% patients with osteoporosis were observed at 6 months and 1, 2, 3, 4, and 5 years after surgery, respectively. Postoperative BMD did not decrease in patients aged ≤54 years, those who had never been smokers, and those with no weight loss after esophagectomy. Multivariate analysis identified that age (≥65 years) at surgery and smoking history were independent risk factors for osteoporosis at 5 years after esophagectomy. Patients with preoperative osteoporosis tended to have worse prognosis in disease‐free survival and overall survival than those without osteoporosis, who were more likely to die due to non‐esophageal cancer. Conclusion Esophageal cancer survivors are more likely to develop osteoporosis after esophagectomy, and preoperative osteoporosis might be associated with prognosis.
- Published
- 2023
- Full Text
- View/download PDF
7. Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody
- Author
-
Shin Urai, Miki Watanabe, Hironori Bando, Yuma Motomura, Masaaki Yamamoto, Motoko Tachihara, Maki Kanzawa, Hidenori Fukuoka, Genzo Iguchi, and Wataru Ogawa
- Subjects
ACTH ,corticotroph ,hypophysitis ,paraneoplastic syndrome ,irAE ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionA recently discovered facet of paraneoplastic adrenocorticotropic hormone (ACTH) deficiency exists in two forms: a paraneoplastic spontaneous isolated ACTH deficiency (IAD) and an immune checkpoint inhibitor (ICI)-related hypophysitis. Autoantibodies against corticotrophs, such as circulating anti-proopiomelanocortin (POMC) antibodies are considered disease markers. However, the number of identified cases was limited, implying that the characteristics of these autoantibodies are not fully understood.MethodsWe investigate circulating autoimmune autoantibodies in detail through a novel case of IAD that developed as a paraneoplastic autoimmune ACTH deficiency.ResultsThe patient developed IAD after 25 weeks of ICI therapy for metastasis of large-cell neuroendocrine carcinoma at 69 years of age. Ectopic ACTH expression and infiltration of CD3+, CD4+, CD8+, and CD20+ lymphocytes were observed in the tumor tissues and circulating anti-POMC antibodies were detected specifically in the patient’s serum. Moreover, detailed analyses of immunofluorescence staining using patient serum revealed that the recognition site of the autoantibody was ACTH25-39, which had not been identified in previous cases of paraneoplastic autoimmune ACTH deficiency.ConclusionThis case involved a combination of paraneoplastic spontaneously acquired IAD and ICI-related hypophysitis occupying the middle ground. Moreover, our study reveals new aspects of anti-POMC antibodies in patients with paraneoplastic ACTH deficiency. This report expands our understanding of the immunological landscape and provides new insights for the identification of antibodies associated with paraneoplastic autoimmune ACTH deficiency.
- Published
- 2023
- Full Text
- View/download PDF
8. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
- Author
-
Shinichiro Hasegawa, Hidenori Takahashi, Hirofumi Akita, Yosuke Mukai, Manabu Mikamori, Kei Asukai, Daisaku Yamada, Hiroshi Wada, Yoshiaki Fujii, Takahito Sugase, Masaaki Yamamoto, Tomohira Takeoka, Naoki Shinno, Hisashi Hara, Takashi Kanemura, Naotsugu Haraguchi, Junichi Nishimura, Chu Matsuda, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, Osamu Ishikawa, and Masato Sakon
- Subjects
DUPAN-II ,Pancreas ,Cancer ,Preoperative chemoradiation therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Duke pancreatic mono-clonal antigen type 2 (DUPAN-II) is a famous tumour maker for pancreatic cancer (PC) as well as carbohydrate antigen 19–9 (CA19-9). We evaluated the clinical implications of DUPAN-II levels as a biological indicator for PC during preoperative chemoradiation therapy (CRT). Methods This retrospective analysis included data from 221 consecutive patients with resectable and borderline resectable PC at diagnosis who underwent preoperative CRT between 2008 and 2017. We focused on 73 patients with elevated pre-CRT DUPAN-II levels (> 230 U/mL; more than 1.5 times the cut-off value for the normal range). Pre- and post-CRT DUPAN-II levels and the changes in DUPAN-II ratio were measured. Results Univariate analysis identified normalisation of DUPAN-II levels after CRT as a significant prognostic factor (hazard ratio [HR] = 2.06, confidence interval [CI] = 1.03–4.24, p = 0.042). Total normalisation ratio was 49% (n = 36). Overall survival (OS) in patients with normalised DUPAN-II levels was significantly longer than that in 73 patients with elevated levels (5-year survival, 55% vs. 21%, p = 0.032) and in 60 patients who underwent tumour resection (5-year survival, 59% vs. 26%, p = 0.039). Conclusion Normalisation of DUPAN-II levels during preoperative CRT was a significant prognostic factor and could be an indicator to monitor treatment efficacy and predict patient prognosis.
- Published
- 2023
- Full Text
- View/download PDF
9. Relation between the insulin lowering rate and changes in bone mineral density: Analysis among subtypes of type 1 diabetes mellitus
- Author
-
Masaki Suzuki, Shin Urai, Hidenori Fukuoka, Yushi Hirota, Masaaki Yamamoto, Yuko Okada, Naoki Yamamoto, Hiroki Shichi, Yasunori Fujita, Keitaro Kanie, Genzo Iguchi, Yutaka Takahashi, and Wataru Ogawa
- Subjects
Bone mineral density ,Subtypes ,Type 1 diabetes mellitus ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Aims/Introduction The bone mineral density in patients with type 1 diabetes mellitus is reduced due to impaired insulin secretion. However, it is unclear whether the rate of bone mineral density reduction is affected by the type 1 diabetes mellitus subtype. This study aimed to clarify the difference in bone mineral density across type 1 diabetes mellitus subtypes: slowly progressive (SP), acute‐onset (AO), and fulminant (F). Methods This was a retrospective, single‐center, cross‐sectional study conducted on 98 adult type 1 diabetes mellitus patients. The main outcome included the bone mineral density Z‐score (BMD‐Z) measured at the lumbar spine and femoral neck. Results The lumbar spine BMD‐Z was lower in the acute‐onset than in the slowly progressive subtype (P = 0.03). No differences were observed when compared with the fulminant subtype. The femoral neck BMD‐Z tended to be higher in the slowly progressive than in the acute‐onset and fulminant subtypes. Multiple regression analyses showed that the lumbar spine BMD‐Z was associated with subtypes (AO vs SP) (P = 0.01), but not subtypes (F vs SP), adjusted for sex, duration, retinopathy, and C‐peptide immunoreactivity (CPR). When the patients were divided into disease duration tertiles, in the first and second tertiles, the CPR levels were lower in the acute‐onset or fulminant than in the slowly progressive subtype. In contrast, the lumbar spine and femoral neck BMD‐Z differed between the acute‐onset and slowly progressive only in the second tertiles (both P
- Published
- 2022
- Full Text
- View/download PDF
10. Risk factors and long‐term postoperative outcomes in patients with postoperative dysphagia after esophagectomy for esophageal cancer
- Author
-
Takahito Sugase, Hiroshi Miyata, Keijiro Sugimura, Takashi Kanemura, Tomohira Takeoka, Masaaki Yamamoto, Naoki Shinno, Hisashi Hara, Takeshi Omori, and Masahiko Yano
- Subjects
dysphagia ,esophageal cancer ,esophagectomy ,pneumonia ,recurrent laryngeal nerve palsy ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Aim Dysphagia is one of the most common complications after esophagectomy. However, no study has investigated the long‐term postoperative outcomes in patients with postoperative dysphagia. Here, we aimed to identify risk factors for postoperative dysphagia and to investigate long‐term postoperative outcomes in such patients. Methods This study included 304 consecutive patients with thoracic esophageal cancer who underwent curative esophagectomy. They were diagnosed with postoperative dysphagia through a contrast videofluoroscopic swallowing study, and postoperative outcomes were compared based on swallowing function. Results In total, 112 patients (37%) were diagnosed with postoperative dysphagia. Older age, low BMI, and recurrent laryngeal nerve palsy were identified as independent risk factors for postoperative dysphagia. In the dysphagia group, a significantly larger number of patients developed in‐hospital pneumonia, and hospital stays were also significantly extended. After discharge, 37 (33%) patients with postoperative dysphagia developed pneumonia. Even more than 1 year after esophagectomy, a significantly larger number of patients (24 patients, 21%) with postoperative dysphagia developed pneumonia compared to those without postoperative dysphagia. Postoperative dysphagia was identified as an independent risk factor for out‐of‐hospital pneumonia. Regarding nutritional status, there was no difference in weight loss 1 year after esophagectomy, but significant weight loss was observed 2 years after esophagectomy in the dysphagia group. Conclusion Postoperative dysphagia was associated with both preoperative patient factors and surgical factors. Moreover, patients with postoperative dysphagia had long‐term and short‐term pneumonia risk. The personalization of long‐term follow‐up through more aggressive rehabilitation and nutritional guidance is required for patients with postoperative dysphagia.
- Published
- 2022
- Full Text
- View/download PDF
11. Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics
- Author
-
Yuiko Inaba, Masaaki Yamamoto, Shin Urai, Masaki Suzuki, Seiji Nishikage, Maki Kanzawa, Yayoi Aoyama, Tomonori Kanda, Katsumi Shigemura, Hironori Bando, Genzo Iguchi, Yasuhiro Nakamura, Masato Fujisawa, Akihisa Imagawa, Hidenori Fukuoka, and Wataru Ogawa
- Subjects
Medicine ,Science - Abstract
Abstract Cases in which bilateral adrenal 123I-Metaiodobenzylguanidine (123I-MIBG) scintigraphy accumulation is sometimes shown, with mildly elevated catecholamine (CA) or metanephrine (MN) levels (within 3 times the upper reference limit) are diagnostic dilemmas. We experienced 3 cases of adrenal incidentalomas with this dilemma in the differential diagnosis. The clinical diagnosis was subclinical Cushing's syndrome in 2 cases, and primary aldosteronism in 1. Despite suspected CA excess in clinical symptoms and imaging findings, the pathological findings of all these tumors were revealed to be cytochrome P450 family 11 subfamily B member 1 (CYP11B1) positive adrenocortical adenomas. Interestingly, adrenal medullary hyperplasia (AMH) was detected in the adrenal parenchyma of all those backgrounds. To clarify the clinical features of such cases, a cross-sectional study was conducted at the Kobe University Hospital from 2014 to 2020. One-hundred sixty-four patients who had undergone 123I-MIBG scintigraphy were recruited. Among them, 10 patients (6.1%) met the above criteria, including the presented 3 cases. Plasma adrenaline, noradrenaline, urinary metanephrine, and normetanephrine had values of 0.05 ± 0.05 ng/mL, 0.63 ± 0.32 ng/mL, 0.22 ± 0.05 mg/day, and 0.35 ± 0.16 mg/day, respectively. Nine cases were complicated with hypertension, and symptoms related to CA excess were observed. Half of them (5 cases) including presented 3 cases had unilateral adrenal tumors. These suggest that in cases of bilateral adrenal uptake on 123I-MIBG, AMH needs to be considered. Adrenocortical adenomas may be associated with AMH and further larger investigation is needed for this pathology.
- Published
- 2022
- Full Text
- View/download PDF
12. A Practical Grading Scale for Predicting Outcomes of Radiosurgery for Dural Arteriovenous Fistulas: JLGK 1802 Study
- Author
-
Hirotaka Hasegawa, Masahiro Shin, Jun Kawagishi, Hidefumi Jokura, Toshinori Hasegawa, Takenori Kato, Mariko Kawashima, Yuki Shinya, Hiroyuki Kenai, Takuya Kawabe, Manabu Sato, Toru Serizawa, Osamu Nagano, Kyoko Aoyagi, Takeshi Kondoh, Masaaki Yamamoto, Shinji Onoue, Kiyoshi Nakazaki, Yoshiyasu Iwai, Kazuhiro Yamanaka, Seiko Hasegawa, Kosuke Kashiwabara, and Nobuhito Saito
- Subjects
central nervous system vascular malformations ,hemorrhagic stroke ,gamma knife radiosurgery ,radiosurgery ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background and Purpose To assess the long-term outcomes of intracranial dural arteriovenous fistula (DAVF) treated with stereotactic radiosurgery (SRS) alone or embolization and SRS (Emb-SRS) and to develop a grading system for predicting DAVF obliteration. Methods This multi-institutional retrospective study included 200 patients with DAVF treated with SRS or Emb-SRS. We investigated the long-term obliteration rate and obliteration-associated factors. We developed a new grading system to estimate the obliteration rate. Additionally, we compared the outcomes of SRS and Emb-SRS by using propensity score matching. Results The 3- and 4-year obliteration rates were 66.3% and 78.8%, respectively. The post-SRS hemorrhage rate was 2%. In the matched cohort, the SRS and Emb-SRS groups did not differ in the rates of obliteration (P=0.54) or post-SRS hemorrhage (P=0.50). In multivariable analysis, DAVF location and cortical venous reflux (CVR) were independently associated with obliteration. The new grading system assigned 2, 1, and 0 points to DAVFs in the anterior skull base or middle fossa, DAVFs with CVR or DAVFs in the superior sagittal sinus or tentorium, and DAVFs without these factors, respectively. Using the total points, patients were stratified into the highest (0 points), intermediate (1 point), or lowest (≥2 points) obliteration rate groups that exhibited 4-year obliteration rates of 94.4%, 71.3%, and 60.4%, respectively (P
- Published
- 2022
- Full Text
- View/download PDF
13. Robotic total gastrectomy with thrombectomy and portal vein reconstruction for gastric cancer and portal vein tumor thrombus
- Author
-
Masaaki Yamamoto, Takeshi Omori, Naoki Shinno, Hisashi Hara, Yosuke Mukai, Takahito Sugase, Tomohira Takeoka, Kei Asukai, Takashi Kanemura, Nozomu Nakai, Shinichiro Hasegawa, Keijiro Sugimura, Hirofumi Akita, Naotsugu Haraguchi, Junichi Nishimura, Hiroshi Wada, Hidenori Takahashi, Chu Matsuda, Masayoshi Yasui, Hiroshi Miyata, and Masayuki Ohue
- Subjects
Gastric cancer ,Portal vein tumor thrombus ,Robot ,Gastrectomy ,Thrombectomy ,Portal vein reconstruction ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Gastric cancer with portal vein tumor thrombus (PVTT) is poor prognosis, and the treatment remains challenging. Regarding surgery, there are only reports of highly invasive laparotomy. We report some techniques of the completely robotic total gastrectomy with thrombectomy and portal vein reconstruction for the patient with gastric cancer and PVTT for the first time. Case presentation A 79-year-old man was diagnosed with a 5-cm gastric cancer on the side of the lesser curvature from the middle of the gastric body to the cardia. Computed tomography revealed a massive PVTT extending from the left gastric vein to the portal trunk (28 x 16 mm). There were no other distant metastases. After 3 cycles of the chemotherapy, the PVTT shrank to 19 x 12 mm. After obtaining informed consent from the patient, robotic total gastrectomy with regional lymphadenectomy and thrombectomy were performed. We used the da Vinci Xi Surgical System. A 3-cm incision was made at the umbilicus, and a wound retractor was placed. Five additional ports were placed. The right side suprapancreatic lymph nodes were performed at the time of the thrombectomy. It was important to identify the precise extent of the PVTT with intraoperative ultrasonography before the thrombectomy. After PVTT identification, the portal trunk was clamped above and below the tumor thrombus with vascular clips. The membrane on the anterior wall of the portal trunk around the PVTT was carefully incised with da Vinci Scissors. The tumor thrombus was completely enucleated without separation. The incised part of the portal trunk was reconstructed with continuous 5-0 synthetic monofilament nonabsorbable polypropylene sutures. After removing the vascular clamps, we made sure there was no leakage from the portal vein and no tumor thrombus remnants with intraoperative ultrasonography. Robotic total gastrectomy with lymphadenectomy and Roux-en-Y reconstruction were performed. The patient was discharged without complications. The patient has remained alive for 30 months after surgery. Conclusions Robotic total gastrectomy with thrombectomy and portal vein reconstruction is a safe, minimally invasive, and precise surgery. It may contribute to improved prognosis of gastric cancer with PVTT when combined with chemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
14. Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study)
- Author
-
Rena Okuno-Ito, Masaaki Yamamoto, Yasunori Sato, Toru Serizawa, Jun Kawagishi, Takashi Shuto, Shoji Yomo, Atsuya Akabane, Kyoko Aoyagi, Takuya Kawabe, Yasuhiro Kikuchi, Kiyoshi Nakasaki, Masazumi Gondo, Yoshinori Higuchi, and Toru Takebayashi
- Subjects
Stereotactic radiosurgery ,Brain metastases ,Renal cancer ,Prognostic grade ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and purpose: The Renal Graded Prognostic Assessment (GPA) is relatively new and has not been sufficiently validated using a different dataset. We thus developed a new grading index, the Renal Brain Metastasis Score (Renal-BMS). Materials and methods: Using our dataset including 262 renal cancer patients with brain metastases (BMs) undergoing stereotactic radiosurgery (SRS) (test series), we validity tested the Renal-GPA. Next, we applied clinical factor-survival analysis to the test series and thereby developed the Renal-BMS. This system was then validated using another series of 352 patients independently undergoing SRS at nine gamma knife facilities in Japan (verification series). Results: Using the test series, with the Renal-GPA, 95% confidence intervals (CIs) of the post-SRS median survival times (MSTs) overlapped between pairs of neighboring subgroups. Among various pre-SRS clinical factors of the test series, six were highly associated with overall survival. Therefore, we assigned scores for six factors, i.e., “KPS ≥ 80%/
- Published
- 2022
- Full Text
- View/download PDF
15. Case report: Late middle-aged features of FAM111A variant, Kenny–Caffey syndrome type 2-suggestive symptoms during a long follow-up
- Author
-
Yuka Ohmachi, Shin Urai, Hironori Bando, Jun Yokoi, Masaaki Yamamoto, Keitaro Kanie, Yuma Motomura, Yasutaka Tsujimoto, Yuriko Sasaki, Yuka Oi, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Genzo Iguchi, Natsumi Uehara, Hidenori Fukuoka, and Wataru Ogawa
- Subjects
FAM111A ,hypoparathyroidism ,Kenny-Caffey syndrome type 2 ,short stature ,sensorineural hearing loss ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Kenny–Caffey syndrome type 2 (KCS2) is an extremely rare skeletal disorder involving hypoparathyroidism and short stature. It has an autosomal dominant pattern of inheritance and is caused by variants in the FAM111 trypsin-like peptidase A (FAM111A) gene. This disease is often difficult to diagnose due to a wide range of more common diseases manifesting hypoparathyroidism and short stature. Herein, we present the case of a 56-year-old female patient with idiopathic hypoparathyroidism and a short stature. The patient was treated for these conditions during childhood. Upon re-evaluating the etiology of KCS2, we suspected that the patient had the disorder because of clinical manifestations, such as cortical thickening and medullary stenosis of the bones, and lack of intellectual abnormalities. Genetic testing identified a heterozygous missense variant in the FAM111A gene (p.R569H). Interestingly, the patient also had bilateral sensorineural hearing loss and vestibular dysfunction, which have been rarely described in previous reports of pediatric cases. In KCS2, inner ear dysfunction due to Eustachian tube dysfunction may progress in middle age or later. However, this disease is now being reported in younger patients. Nevertheless, our case may be instructive of how such cases emerge chronically after middle age. Herein, we also provide a literature review of KCS2.
- Published
- 2023
- Full Text
- View/download PDF
16. Novel genes and variants associated with congenital pituitary hormone deficiency in the era of next-generation sequencing
- Author
-
Hironori Bando, Shin Urai, Keitaro Kanie, Yuriko Sasaki, Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, and Sally A. Camper
- Subjects
combined pituitary hormone deficiency ,hypopituitarism ,next-generation sequencing ,pituitary development ,genetic diagnosis ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Combined pituitary hormone deficiency (CPHD) is not a rare disorder, with a frequency of approximately 1 case per 4,000 live births. However, in most cases, a genetic diagnosis is not available. Furthermore, the diagnosis is challenging because no clear correlation exists between the pituitary hormones affected and the gene(s) responsible for the disorder. Next-generation sequencing (NGS) has recently been widely used to identify novel genes that cause (or putatively cause) CPHD. This review outlines causative genes for CPHD that have been newly reported in recent years. Moreover, novel variants of known CPHD-related genes (POU1F1 and GH1 genes) that contribute to CPHD through unique mechanisms are also discussed in this review. From a clinical perspective, variants in some of the recently identified causative genes result in extra-pituitary phenotypes. Clinical research on the related symptoms and basic research on pituitary formation may help in inferring the causative gene(s) of CPHD. Future NGS analysis of a large number of CPHD cases may reveal new genes related to pituitary development. Clarifying the causative genes of CPHD may help to understand the process of pituitary development. We hope that future innovations will lead to the identification of genes responsible for CPHD and pituitary development.
- Published
- 2022
- Full Text
- View/download PDF
17. Laparoscopic-assisted disinvagination and polypectomy for multiple intussusceptions induced by small intestinal polyps in patients with Peutz-Jeghers syndrome: a case report
- Author
-
Masaaki Yamamoto, Kazuya Iwamoto, Rei Suzuki, Yosuke Mukai, Tomohira Takeoka, Kei Asukai, Naoki Shinno, Hisashi Hara, Takashi Kanemura, Nozomu Nakai, Shinichiro Hasegawa, Keijiro Sugimura, Naotsugu Haraguchi, Junichi Nishimura, Hiroshi Wada, Hidenori Takahashi, Chu Matsuda, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, and Masaru Murata
- Subjects
Peutz–Jeghers syndrome ,Intussusception ,Polyposis ,Laparoscopic-assisted polypectomy ,Disinvagination ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Peutz–Jeghers syndrome (PJS) is a very rare autosomal dominant genetic disorder characterized by hamartomatous polyps in the gastrointestinal tract and hyperpigmentation of the lips, hands, and feet. The hamartomatous polyps in the small intestine often cause intussusception and bleeding. Case presentation A 62-year-old male was hospitalized for treatment of deep vein thrombosis and pulmonary embolism. In the small intestine, computed tomography showed three small polyps with intussusceptions. Since the patient had gastrointestinal polyposis and pigmentation of his lips, fingers, and toes, he was diagnosed with PJS. After an inferior vena cava filter was placed, he underwent laparoscopic-assisted surgery. The polyps causing intussusception were resected as far as possible without intestinal resection, since they had caused progressive anemia and might cause intestinal obstruction in the future. The patient was discharged from the hospital on postoperative day 9 without complications. Conclusions Laparoscopic-assisted disinvagination and polypectomy is a useful, minimally invasive treatment for multiple intussusceptions caused by small intestinal polyps in patients with PJS.
- Published
- 2021
- Full Text
- View/download PDF
18. The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment
- Author
-
Naoki Yamamoto, Shin Urai, Hidenori Fukuoka, Masaaki Yamamoto, Kenichi Yoshida, Masaki Suzuki, Hiroki Shichi, Yasunori Fujita, Keitaro Kanie, Genzo Iguchi, Yutaka Takahashi, and Wataru Ogawa
- Subjects
acromegaly ,quality of life ,arthropathy ,older patients ,AcroQoL ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
ContextWith the increasing number of older patients with acromegaly, it is important to understand the effects of aging on the quality of life (QoL) in acromegaly.ObjectiveTo investigate the factors associated with the QoL of older acromegaly patients.DesignThis was a single-center, retrospective, cross-sectional study conducted between 2014 and 2019.MethodsAmong 90 acromegaly patients at Kobe University Hospital, 74 who had completed the QoL evaluation under treatment were enrolled (age = 62.0 [50.7–70.0], female 52%). SF-36 and the AcroQoL questionnaire were used to quantify QoL. The patients were divided into two groups: the young and middle-aged group, aged
- Published
- 2022
- Full Text
- View/download PDF
19. A Cohort Study of Stereotactic Radiosurgery Results for Patients With 5 to 15 Versus 2 to 4 Brain Metastatic Tumors
- Author
-
Masaaki Yamamoto, MD, PhD, Yasunori Sato, PhD, Yoshinori Higuchi, MD, PhD, Hidetoshi Kasuya, MD, PhD, and Bierta E. Barfod, MD
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: The role of stereotactic radiosurgery (SRS) alone for patients with ≥5 brain metastases is not fully understood. The objective of the study was to compare SRS-alone treatment results for 2 to 4 versus 5 to 15 tumors. Methods and Materials: This was an institutional review board–approved, retrospective cohort study using our prospectively accumulated database including 1150 patients with 2 to 4 tumors and 939 with 5 to 15 tumors who underwent Gamma Knife SRS during a 20-year period (1998-2018). The Kaplan-Meier method was used to determine post-SRS survival times, and competing risk analyses were applied to estimate cumulative incidences of the secondary endpoints. Results: The post-SRS median survival time was slightly longer in the group with 2 to 4 tumors (8.1 months) than in that with 5 to 15 tumors (7.2 months, P = .0010). Median survival time differences were statistically significant for non-small cell lung cancer, gastrointestinal tract cancer, and others but not for small cell lung cancer, breast cancer, and kidney cancer. Multivariable analysis demonstrated female sex, better Karnofsky Performance Status score, non-small cell lung cancer (vs gastrointestinal tract cancer), younger age, controlled primary cancer, and no extracerebral metastases to be significant predictors of a longer survival period in both tumor number groups. Crude and cumulative incidences of salvage whole brain radiation therapy were significantly higher in the group with 5 to 15 tumors than in that with 2 to 4 tumors, although those of other secondary endpoints were similar to or lower in the 5 to 15 tumor number group than those in the group with 2 to 4 tumors. Conclusions: We conclude that carefully selected patients with ≥5 to 15 tumors are not unfavorable candidates for SRS alone.
- Published
- 2020
- Full Text
- View/download PDF
20. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
- Author
-
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D. Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K. Wong, Mototsugu Oya, and Donald Kufe
- Subjects
Science - Abstract
MUC1-C is overexpressed in castration-resistant prostate cancer and neuroendocrine prostate cancer. Here, the authors show that MUC1-C drives lineage plasticity through MYC and BRN2, inducing neuroendocrine features and stemness in prostate cancer.
- Published
- 2020
- Full Text
- View/download PDF
21. Stereotactic Radiosurgery Results for Patients With Brain Metastases From Gastrointestinal Cancer: A Retrospective Cohort Study of 802 Patients With GI-GPA Validity Test
- Author
-
Masaaki Yamamoto, MD, PhD, Toru Serizawa, MD, PhD, Yasunori Sato, PhD, Yoshinori Higuchi, MD, PhD, Takuya Kawabe, MD, PhD, Hidetoshi Kasuya, MD, PhD, and Bierta E. Barfod, MD
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: The role of stereotactic radiosurgery (SRS) alone for patients with gastrointestinal (GI) cancer has yet to be established based on a large patient series. We analyzed post-SRS treatment results and reappraised whether either the GI graded prognostic assessment (GPA) system or modified-recursive partitioning assessment (M-RPA) system was applicable to our 802 SRS-treated patients with GI cancer with brain metastases. Methods and Materials: This was an institutional review board approved retrospective cohort study 2 database comprising 802 patients with GI cancer treated with gamma-knife SRS by 2 experienced neurosurgeons during the 1998 to 2018 period. The Kaplan-Meier method was applied to determine post-SRS survival times, and competing risk analyses were used to estimate cumulative incidences of the secondary endpoints. Results: The median survival time (MST; months) after SRS was 5.7. With the GI GPA system, MSTs were 3.5/6.1/7.7/11.0 in the 4 subgroups, that is, 0 to 1.0/1.5 to 2.0/2.5 to 3.0/3.5 to 4.0, respectively (stratified P < .0001). However, there was no significant MST difference between 2 of the subgroups, GI-GPA 1.5 to 2.0 and 2.5 to 3.0 (P = .073). In contrast, using the M-RPA system, 3 plot lines corresponding to the 3 subgroups showed no overlap and the MST differences between the subgroups with M-RPA were 1 + 2a versus 2b (P < .0001) and 2b versus 2c + 3 (P < .0001). Better Karnofsky performance status score, solitary tumor, well-controlled primary cancer, and the absence of extracerebral metastases were shown by multivariable analysis to be significant predictors of longer survival. The crude and cumulative incidences of neurologic death, neurologic deterioration, local recurrence, salvage whole brain radiation therapy, and SRS-related complications did not differ significantly between the 2 patient groups, with upper and lower GI cancers. Conclusions: This study clearly demonstrated the usefulness of the GI GPA. Patients with GI GPA 1.5 to 2.0 or better or M-RPA 2b or better are considered to be favorable candidates for treatment with SRS alone.
- Published
- 2021
- Full Text
- View/download PDF
22. Author Correction: Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics
- Author
-
Yuiko Inaba, Masaaki Yamamoto, Shin Urai, Masaki Suzuki, Seiji Nishikage, Maki Kanzawa, Yayoi Aoyama, Tomonori Kanda, Katsumi Shigemura, Hironori Bando, Genzo Iguchi, Yasuhiro Nakamura, Masato Fujisawa, Akihisa Imagawa, Hidenori Fukuoka, and Wataru Ogawa
- Subjects
Medicine ,Science - Published
- 2022
- Full Text
- View/download PDF
23. Aggressive Cushing’s Disease: Molecular Pathology and Its Therapeutic Approach
- Author
-
Masaaki Yamamoto, Takahiro Nakao, Wataru Ogawa, and Hidenori Fukuoka
- Subjects
Cushing’s disease (CD) ,aggressiveness/physiology ,pathology ,medical treatment/surgical treatment ,targeted therapy ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Cushing’s disease is a syndromic pathological condition caused by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) mediated by hypercortisolemia. It may have a severe clinical course, including infection, psychiatric disorders, hypercoagulability, and metabolic abnormalities, despite the generally small, nonaggressive nature of the tumors. Up to 20% of ACTHomas show aggressive behavior, which is related to poor surgical outcomes, postsurgical recurrence, serious clinical course, and high mortality. Although several gene variants have been identified in both germline and somatic changes in Cushing’s disease, the pathophysiology of aggressive ACTHomas is poorly understood. In this review, we focused on the aggressiveness of ACTHomas, its pathology, the current status of medical therapy, and future prospects. Crooke’s cell adenoma (CCA), Nelson syndrome, and corticotroph pituitary carcinoma are representative refractory pituitary tumors that secrete superphysiological ACTH. Although clinically asymptomatic, silent corticotroph adenoma is an aggressive ACTH-producing pituitary adenoma. In this review, we summarize the current understanding of the pathophysiology of aggressive ACTHomas, including these tumors, from a molecular point of view based on genetic, pathological, and experimental evidence. The treatment of aggressive ACTHomas is clinically challenging and usually resistant to standard treatment, including surgery, radiotherapy, and established medical therapy (e.g., pasireotide and cabergoline). Temozolomide is the most prescribed pharmaceutical treatment for these tumors. Reports have shown that several treatments for patients with refractory ACTHomas include chemotherapy, such as cyclohexyl-chloroethyl-nitrosourea combined with 5-fluorouracil, or targeted therapies against several molecules including vascular endothelial growth factor receptor, cytotoxic T lymphocyte antigen 4, programmed cell death protein 1 (PD-1), and ligand for PD-1. Genetic and experimental evidence indicates that some possible therapeutic candidates are expected, such as epidermal growth factor receptor tyrosine kinase inhibitor, cyclin-dependent kinase inhibitor, and BRAF inhibitor. The development of novel treatment options for aggressive ACTHomas is an emerging task.
- Published
- 2021
- Full Text
- View/download PDF
24. Intractable epilepsy associated with angiographic obliteration of a medial temporal arteriovenous malformation following stereotactic radiosurgery
- Author
-
Naoki Maehara, Takato Morioka, Toshiyuki Amano, Satoshi O. Suzuki, Masaaki Yamamoto, and Sei Haga
- Subjects
Surgery ,RD1-811 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
We present a case with recurrence of intractable complex partial epilepsy, despite angiographic obliteration of a cerebral arteriovenous malformation in the left medial temporal lobe following gamma knife radiosurgery. Preoperative memory function was normal, with no evidence of hippocampal atrophy by magnetic resonance imaging. Intraoperative electrocorticography demonstrated two independent foci of paroxysmal activity in the lateral and medial temporal lobes. As preoperative magnetic resonance imaging demonstrated subcortical hyperintensity, the lateral temporal lobe was resected. Histologically, there was evidence of subcortical myelin pallor, likely resulting from ischemic damage associated with hemodynamic changes following radiosurgery. As there was a decrease in the frequency of paroxysmal discharges in the hippocampus following arteriovenous malformation nidus removal, the hippocampus was preserved. Histological examination of the nidus revealed that some of the vessels had patent lumina, while ischemia affecting the neighboring hippocampus was considered to show improvement. A good seizure outcome was obtained. In summary, perioperative multimodal examinations, including intraoperative electrocorticography, revealed various epileptogenic mechanisms, probably related to myelin pallor in the lateral temporal lobe and focal ischemia secondary to patent AVM in the medial temporal lobe, of this patient. Keywords: Intraoperative electrocorticography, Myelin pallor, Hippocampus, Patent arteriovenous malformation
- Published
- 2018
- Full Text
- View/download PDF
25. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
- Author
-
Kwok-Kin Wong, Song Liu, Qiang Hu, Mark Long, Donald Kufe, Nami Yamashita, Atsushi Fushimi, Masaaki Yamamoto, Tsuyoshi Hata, Masayuki Hagiwara, and Atrayee Bhattacharya
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Immune checkpoint inhibitors (ICIs) have had a profound impact on the treatment of many tumors; however, their effectiveness against triple-negative breast cancers (TNBCs) has been limited. One factor limiting responsiveness of TNBCs to ICIs is a lack of functional tumor-infiltrating lymphocytes (TILs) in ‘non-inflamed’ or ‘cold’ tumor immune microenvironments (TIMEs), although by unknown mechanisms. Targeting MUC1-C in a mouse transgenic TNBC tumor model increases cytotoxic tumor-infiltrating CD8+ T cells (CTLs), supporting a role for MUC1-C in immune evasion. The basis for these findings and whether they extend to human TNBCs are not known.Methods Human TNBC cells silenced for MUC1-C using short hairpin RNAs (shRNAs) were analyzed for the effects of MUC1-C on global transcriptional profiles. Differential expression and rank order analysis was used for gene set enrichment analysis (GSEA). Gene expression was confirmed by quantitative reverse-transcription PCR and immunoblotting. The The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets were analyzed for effects of MUC1 on GSEA, cell-type enrichment, and tumor immune dysfunction and exclusion. Single-cell scRNA-seq datasets of TNBC samples were analyzed for normalized expression associations between MUC1 and selected genes within tumor cells.Results Our results demonstrate that MUC1-C is a master regulator of the TNBC transcriptome and that MUC1-C-induced gene expression is driven by STAT1 and IRF1. We found that MUC1-C activates the inflammatory interferon (IFN)-γ-driven JAK1→STAT1→IRF1 pathway and induces the IDO1 and COX2/PTGS2 effectors, which play key roles in immunosuppression. Involvement of MUC1-C in activating the immunosuppressive IFN-γ pathway was extended by analysis of human bulk and scRNA-seq datasets. We further demonstrate that MUC1 associates with the depletion and dysfunction of CD8+ T cells in the TNBC TIME.Conclusions These findings demonstrate that MUC1-C integrates activation of the immunosuppressive IFN-γ pathway with depletion of TILs in the TNBC TIME and provide support for MUC1-C as a potential target for improving TNBC treatment alone and in combination with ICIs. Of translational significance, MUC1-C is a druggable target with chimeric antigen receptor (CAR) T cells, antibody-drug conjugates (ADCs) and a functional inhibitor that are under clinical development.
- Published
- 2021
- Full Text
- View/download PDF
26. The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing’s Disease
- Author
-
Hidenori Fukuoka, Hiroki Shichi, Masaaki Yamamoto, and Yutaka Takahashi
- Subjects
adrenocorticotrophic hormone ,Cushing’s disease ,glucocorticoid resistance ,ectopic ACTH syndrome ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Cushing’s disease caused due to adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (ACTHomas) leads to hypercortisolemia, resulting in increased morbidity and mortality. Autonomous ACTH secretion is attributed to the impaired glucocorticoid negative feedback (glucocorticoid resistance) response. Interestingly, other conditions, such as ectopic ACTH syndrome (EAS) and non-neoplastic hypercortisolemia (NNH, also known as pseudo-Cushing’s syndrome) also exhibit glucocorticoid resistance. Therefore, to differentiate between these conditions, several dynamic tests, including those with desmopressin (DDAVP), corticotrophin-releasing hormone (CRH), and Dex/CRH have been developed. In normal pituitary corticotrophs, ACTH synthesis and secretion are regulated mainly by CRH and glucocorticoids, which are the ACTH secretion-stimulating and -suppressing factors, respectively. These factors regulate ACTH synthesis and secretion through genomic and non-genomic mechanisms. Conversely, glucocorticoid negative feedback is impaired in ACTHomas, which could be due to the overexpression of 11β-HSD2, HSP90, or TR4, or loss of expression of CABLES1 or nuclear BRG1 proteins. Genetic analysis has indicated the involvement of several genes in the etiology of ACTHomas, including USP8, USP48, BRAF, and TP53. However, the association between glucocorticoid resistance and these genes remains unclear. Here, we review the clinical aspects and molecular mechanisms of ACTHomas and compare them to those of other related conditions.
- Published
- 2020
- Full Text
- View/download PDF
27. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
- Author
-
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D. Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok K. Wong, Mototsugu Oya, and Donald Kufe
- Subjects
Science - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
28. The Essential Role of SIRT1 in Hypothalamic-Pituitary Axis
- Author
-
Masaaki Yamamoto and Yutaka Takahashi
- Subjects
SIRT1 ,adaptation ,calorie restriction ,hypothalamus ,pituitary ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
The endocrine system plays an essential role in the physiological adaptation to malnutrition. The adaptive response of various hormones directs the energy utilization toward the survival functions and away from growth and reproduction. Particularly, the hypothalamic pituitary axis plays an integral and a central role in the regulation of endocrine organs. Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylase that is activated in response to calorie restriction (CR). SIRT1 is involved in cellular processes via the deacetylation of histone as well as various transcription factors and signal transduction molecules and thereby modulates the endocrine/metabolic functions. There is much evidence to demonstrate clearly that SIRT1 in the hypothalamus, pituitary gland, and other target organs modifies the synthesis, secretion, and activities of hormones and in turn induces the adaptive responses. In this review, we discussed the role of SIRT1 in the hypothalamic pituitary axis and its pathophysiological significance.
- Published
- 2018
- Full Text
- View/download PDF
29. A Case of Old Age-Onset Generalized Pustular Psoriasis with a Deficiency of IL-36RN (DITRA) Treated by Granulocyte and Monocyte Apheresis
- Author
-
Chiharu Tominaga, Masaaki Yamamoto, Yasutomo Imai, and Kiyofumi Yamanishi
- Subjects
Pustular psoriasis ,Psoriasis vulgaris ,IL-36RN ,Mutation ,Granulocyte and monocyte apheresis ,Cytokines ,Dermatology ,RL1-803 - Abstract
A 78-year-old woman who had been suffering from psoriasis vulgaris for 31 years was admitted to hospital because of her erythroderma. A toxic eruption was suspected and she was treated with prednisolone 30 mg daily. However, it was ineffective and, suspecting psoriatic erythroderma, cyclosporine 150 mg daily was administered with tapering of the prednisolone. Two weeks after a dose reduction of cyclosporine to 100 mg/day, erythroderma with widespread generalized pustules and fever developed. Histology of a biopsy revealed inflammatory infiltrates in the skin with a spongiform pustule of Kogoj, which was consistent with generalized pustular psoriasis (GPP). Her pustules improved with additional etretinate 20 mg/day, but the erythroderma persisted and she consulted us. Three sessions of granulocyte and monocyte apheresis once weekly were effective for her condition and decreased her serum levels of IL-6 and IL-8. She had homozygous mutations of c.[28C>T] in IL36RN which cause p.[Arg10Ter]. She is the oldest reported case of GPP with a deficiency of interleukin-36 receptor antagonist (DITRA), although GPP in DITRA has been suggested to usually occur in younger cases with no pre-existing psoriasis vulgaris.
- Published
- 2015
- Full Text
- View/download PDF
30. Anomalous Sound Detection Based on Machine Activity Detection.
- Author
-
Tomoya Nishida, Kota Dohi, Takashi Endo, Masaaki Yamamoto, and Yohei Kawaguchi
- Published
- 2022
31. Hierarchical Conditional Variational Autoencoder Based Acoustic Anomaly Detection.
- Author
-
Harsh Purohit, Takashi Endo, Masaaki Yamamoto, and Yohei Kawaguchi
- Published
- 2022
32. Environmental Sound Extraction Using Onomatopoeic Words.
- Author
-
Yuki Okamoto, Shota Horiguchi, Masaaki Yamamoto, Keisuke Imoto, and Yohei Kawaguchi
- Published
- 2022
- Full Text
- View/download PDF
33. Audio-Visual Speech Enhancement Method Conditioned in the Lip Motion and Speaker-Discriminative Embeddings.
- Author
-
Koichiro Ito, Masaaki Yamamoto, and Kenji Nagamatsu
- Published
- 2021
- Full Text
- View/download PDF
34. MIMII DG: Sound Dataset for Malfunctioning Industrial Machine Investigation and Inspection for Domain Ggeneralization Task.
- Author
-
Kota Dohi, Tomoya Nishida, Harsh Purohit, Ryo Tanabe, Takashi Endo, Masaaki Yamamoto, Yuki Nikaido, and Yohei Kawaguchi
- Published
- 2022
35. Description and Discussion on DCASE 2022 Challenge Task 2: Unsupervised Anomalous Sound Detection for Machine Condition Monitoring Applying Domain Generalization Techniques.
- Author
-
Kota Dohi, Keisuke Imoto, Noboru Harada, Daisuke Niizumi, Yuma Koizumi, Tomoya Nishida, Harsh Purohit, Ryo Tanabe, Takashi Endo, Masaaki Yamamoto, and Yohei Kawaguchi
- Published
- 2022
36. Frame transmission time control for TDMA-based ethernet.
- Author
-
Naoto Hagino, Masaaki Yamamoto, and Takahiro Yakoh
- Published
- 2018
- Full Text
- View/download PDF
37. Environmental Sound Extraction Using Onomatopoeia.
- Author
-
Yuki Okamoto, Shota Horiguchi, Masaaki Yamamoto, Keisuke Imoto, and Yohei Kawaguchi
- Published
- 2021
38. Integration of existing ethernet devices into time-division-multiplexing ethernet.
- Author
-
Masaaki Yamamoto and Takahiro Yakoh
- Published
- 2017
- Full Text
- View/download PDF
39. Vehicle's Weight Estimation Using Smartphone's Acceleration Data to Control Overloading.
- Author
-
Phong Xuan Nguyen, Takayuki Akiyama, Hiroki Ohashi, Masaaki Yamamoto, and Akiko Sato
- Published
- 2018
- Full Text
- View/download PDF
40. Survey of glucocorticoid dose escalation in patients with adrenal insufficiency during the peri-COVID-19 vaccination period
- Author
-
Hironori Bando, Masaaki Yamamoto, Michiko Takahashi, Keitaro Kanie, Yuriko Sasaki, Yuka Oi, Seiji Tomofuji, Kaori Hozumi, Seiji Nishikage, Shin Urai, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Genzo Iguchi, Hidenori Fukuoka, and Wataru Ogawa
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Vaccination ,COVID-19 ,Steroid cover ,Adrenal insufficiency - Abstract
There is uncertainty regarding the need for COVID-19 peri-vaccination glucocorticoid coverage in patients with adrenal insufficiency. In this survey conducted in a single tertiary medical institution, 167 consecutive outpatients taking physiological glucocorticoids because of adrenal insufficiency were included. The patients declared if they developed an adrenal crisis after vaccination, and the amount and duration of an increase in their glucocorticoid dosage, if any. None of the patients without preventive glucocorticoid increase suffered an adrenal crisis after COVID-19 vaccination. Only 8.3% (14 cases) and 27.5% (46 cases) of the patients needed to escalate the dose of glucocorticoids when systemic symptoms appeared after the first and second injections, respectively. Glucocorticoids were increased in patients
- Published
- 2023
41. Long‐term changes in bone mineral density in postoperative patients with esophageal cancer
- Author
-
Takahito Sugase, Keijiro Sugimura, Takashi Kanemura, Tomohira Takeoka, Masaaki Yamamoto, Naoki Shinno, Hisashi Hara, Takeshi Omori, Masayoshi Yasui, and Hiroshi Miyata
- Subjects
Gastroenterology ,Surgery - Published
- 2022
42. Performance evaluation of TCP/IP over time-division multiplexing Ethernet.
- Author
-
Kana Otawara, Masaaki Yamamoto, and Takahiro Yakoh
- Published
- 2016
- Full Text
- View/download PDF
43. Safety and efficacy of preoperative indocyanine green fluorescence marking in laparoscopic gastrectomy for proximal gastric and esophagogastric junction adenocarcinoma (ICG MAP study)
- Author
-
Takeshi, Omori, Hisashi, Hara, Naoki, Shinno, Masaaki, Yamamoto, Takashi, Kanemura, Tomohira, Takeoka, Hirofumi, Akita, Hiroshi, Wada, Masayoshi, Yasui, Chu, Matsuda, Junichi, Nishimura, Masayuki, Ohue, Masato, Sakon, and Hiroshi, Miyata
- Subjects
Indocyanine Green ,Esophageal Neoplasms ,Gastrectomy ,Stomach Neoplasms ,Humans ,Laparoscopy ,Surgery ,Esophagogastric Junction ,Adenocarcinoma ,Retrospective Studies - Abstract
The incidence of adenocarcinoma of the esophagogastric junction (AEG) and proximal gastric cancer (PGC) is rising worldwide. Recently, the use of indocyanine green (ICG) tracer-guided surgery has been reported; however, its efficacy for total/proximal gastrectomy has not been clarified. We evaluated the feasibility and safety of ICG fluorescent marking for tumor localization in AEG/PGC treatment by laparoscopic surgery.We enrolled patients with AEG/PGC from October 2016 to March 2019 from a prospectively registered database. On the day before surgery, ICG markings were made at four locations just at the edge of the tumor by gastrointestinal fiberscope examination. Surgery was performed while viewing the fluorescence image of ICG, and the proximal portions of the esophagus and the distal portion of the stomach were resected at the edge of the area where ICG had spread.We enrolled 130 patients with AEG/PGC. Overall, 107 patients were eventually included in the study: AEG n = 64 (60%) and PGC n = 43 (40%). ICG markings were detected intraoperatively in all cases, and cancer invasion into the resection lines of the esophagus and stomach, performed based on ICG fluorescence images, was negative in all cases. The median visible range of ICG fluorescence was 22.5 mm. ICG diffusion expanded 20 mm proximal for AEG. There were no adverse events associated with endoscopic ICG injection.ICG fluorescence imaging is feasible and safe and can potentially be used as a tumor-marking agent for determining the surgical resection line for total/proximal gastrectomy in AEG and PGC treatment.
- Published
- 2022
44. Risk for Hemorrhage the First 2 Years After Gamma Knife Surgery for Arteriovenous Malformations: An Update
- Author
-
Bengt, Karlsson, Hidefumi, Jokura, Huai-Che, Yang, Masaaki, Yamamoto, Roberto, Martinez-Alvarez, Jun, Kawagishi, Wan-Yuo, Guo, Wen-Yuh, Chung, Michael, Söderman, Tseng Tsai, Yeo, and Ingmar, Lax
- Subjects
Intracranial Arteriovenous Malformations ,Treatment Outcome ,Risk Factors ,Humans ,Female ,Surgery ,Neurology (clinical) ,Radiosurgery ,Radiation Injuries ,Cerebral Hemorrhage ,Retrospective Studies ,Follow-Up Studies - Abstract
Knowledge about the natural course of brain arteriovenous malformations (AVMs) have increased during the past 20 years, as has the number of AVMs treated, especially larger ones. It is thus timely to again analyze the risk for hemorrhage after Gamma Knife Surgery (GKS).To confirm or contradict conclusions drawn 20 years ago regarding factors that affect the risk for post-GKS hemorrhage.The outcome after GKS was studied in 5037 AVM patients followed for up to 2 years. The relation between post-treatment hemorrhage rate and a number of patient, AVM, and treatment parameters was analyzed. The results were also compared with the results from our earlier study.The annual post-treatment hemorrhage rate was 2.4% the first 2 years after GKS. Large size, low treatment dose, and old age were independent risk factors for AVM hemorrhage. After having compensated for the factors above, peripheral AVM location and female sex, at least during their child bearing ages, were factors associated with a lower post-GKS hemorrhage rate.Large AVMs (5 cm 3 ) treated with low doses (≤16 Gy) had higher and small AVMs treated with high doses a lower risk for hemorrhage as compared with untreated AVMs. This was detectable within the first 6 months after GKS. No difference in hemorrhage rate could be detected for the other AVMs. Based on our findings, it is advisable to prescribe16 Gy to larger AVMs, assuming that the risk for radiation-induced complications can be kept at an acceptable level.
- Published
- 2022
45. The DOLFIN method: a novel laparoscopic Billroth-I gastroduodenostomy for gastric cancer with duodenal invasion
- Author
-
Naoki Shinno, Takeshi Omori, Hisashi Hara, Masaaki Yamamoto, Kohei Fujita, Takashi Kanemura, Tomohira Takeoka, Takahito Sugase, Masayoshi Yasui, Chu Matsuda, Hiroshi Wada, Junichi Nishimura, Naotsugu Haraguchi, Hirofumi Akita, Shinichiro Hasegawa, Nozomu Nakai, Kei Asukai, Yousuke Mukai, Hiroshi Miyata, Masayuki Ohue, and Masato Sakon
- Subjects
Stomach Neoplasms ,Gastrectomy ,Duodenum ,Anastomosis, Surgical ,Humans ,Laparoscopy ,Surgery ,Retrospective Studies - Abstract
Laparoscopic Billroth-I gastroduodenostomy using a delta-shaped anastomosis is safe and feasible. However, it is often difficult to perform in patients who have a short posterior wall of the duodenum. Thus, we have developed a new method named duodenal overlap functional anastomosis with linear stapler (DOLFIN). We hereby report the technical details of the new method and our preliminary experience performing it.After the completion of lymphadenectomy, the duodenum was transected craniocaudally with an endoscopic linear stapler. The hepatoduodenal mesentery was dissected approximately 4 cm along the duodenal bulb, and the anastomosis between the posterior wall of the stomach and the lesser curvature of the duodenum was created. The common entry hole was then transected using an endoscopic linear stapler, and the anastomosis was finally completed.There were 36 patients with gastric cancer who underwent laparoscopic distal gastrectomy (LDG) or robotic distal gastrectomy (RDG) with B-I reconstruction using DOLFIN. There were no postoperative complications classified as C-D grade 3 or more and complications related to anastomosis, such as anastomotic leak or stenosis.Our DOLFIN gastroduodenostomy can be performed safely. In addition, it results in good postoperative outcomes. A long-term comparative study is required to further evaluate the clinical usefulness of this method.
- Published
- 2022
46. A retrospective cohort study of stereotactic radiosurgery for vestibular schwannomas: Comparison of two age groups (75 years or older vs. 65-74 years).
- Author
-
Shinya Watanabe, Masaaki Yamamoto, Hitoshi Aiyama, Narushi Sugii, Masahide Matsuda, Hiroyoshi Akutsu, and Eiichi Ishikawa
- Subjects
ACOUSTIC neuroma ,FACIAL nerve ,AGE groups ,RADIATION doses ,OLDER people ,STEREOTACTIC radiosurgery - Abstract
Background: Treatment outcome data of stereotactic radiosurgery (SRS) for vestibular schwannomas (VS) in patients =75 years (late elderly) are lacking. Approximately 39% of patients =75 years with VS were reported to experience severe facial palsy after surgical removal. This study compared the treatment outcomes post-SRS for VS between patients =75 and 65-74 years (early elderly). Methods: Of 453 patients who underwent gamma knife SRS for VS, 156 were =65 years old. The late and early elderly groups comprised 35 and 121 patients, respectively. The median tumor volume was 4.4 cc, and the median radiation dose was 12.0 Gy. Results: The median follow-up periods were 37 and 56 months in the late and early elderly groups, respectively. Tumor volume control was observed in 27 (88%) and 95 (83%) patients (P = 0.78), while additional procedures were required in 2 (6%) and 6 (6%) patients (P = 1.00) in the late and early elderly groups, respectively. At the 60th and 120th months post-SRS, the cumulative tumor control rates were 87%, 75%, 85%, and 73% (P = 0.81), while the cumulative clinical control rates were 93% and 87%, 95%, and 89% (P = 0.80), in the late and early elderly groups, respectively. In the early elderly group, two patients experienced facial pain, and one experienced facial palsy post-SRS; there were no adverse effects in the late elderly group (both P = 1.00). Conclusion: SRS is effective for VS and beneficial in patients =75 years old as it preserves the facial nerve. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Composite paraganglioma-ganglioneuroma with atypical catecholamine profile and phenylethanolamine N-methyltransferase expression: a case report and literature review.
- Author
-
Yuriko Sasaki, Maki Kanzawa, Masaaki Yamamoto, Keitaro Kanie, Hironori Bando, Kei Yoshino, Yushi Hirota, Katsumi Shigemura, Masato Fujisawa, Wataru Ogawa, and Hidenori Fukuoka
- Published
- 2024
- Full Text
- View/download PDF
48. Comparison of First-Line Radiosurgery for Small-Cell and Non-Small Cell Lung Cancer Brain Metastases (Cross-FIRE)
- Author
-
Chad G Rusthoven, Alyse W Staley, Dexiang Gao, Shoji Yomo, Denise Bernhardt, Narine Wandrey, Rami El Shafie, Anna Kraemer, Oscar Padilla, Veronica Chiang, Andrew M Faramand, Joshua D Palmer, Brad E Zacharia, Rodney E Wegner, Jona A Hattangadi-Gluth, Antonin Levy, Kenneth Bernstein, David Mathieu, Daniel N Cagney, Michael D Chan, Inga S Grills, Steve Braunstein, Cheng-chia Lee, Jason P Sheehan, Christien Kluwe, Samir Patel, Lia M Halasz, Nicolaus Andratschke, Christopher P Deibert, Vivek Verma, Daniel M Trifiletti, Christopher P Cifarelli, Jürgen Debus, Stephanie E Combs, Yasunori Sato, Yoshinori Higuchi, Kyoko Aoyagi, Paul D Brown, Vida Alami, Ajay Niranjan, L Dade Lunsford, Douglas Kondziolka, D Ross Camidge, Brian D Kavanagh, Tyler P Robin, Toru Serizawa, and Masaaki Yamamoto
- Subjects
Cancer Research ,Oncology - Abstract
Introduction Historical reservations regarding radiosurgery (SRS) for small-cell-lung-cancer (SCLC) brain metastases (BrM) include concerns for short-interval/diffuse CNS-progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small-cell-lung-cancer (NSCLC) where SRS is well established. Methods Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000-2022 were retrospectively collected (N=892-SCLC/N=4,785-NSCLC). Data from the prospective JLGK0901 SRS trial were analyzed as a comparison cohort (N=98-SCLC/N=794-NSCLC). OS and CNS-progression were analyzed using Cox-Proportional-Hazard and Fine-Gray models, respectively, with multivariable (MV) adjustment (including age/sex/performance-status/year/extracranial disease/BrM-number/BrM-volume). Mutation-stratified analyses were performed in propensity score-matched (PSM) retrospective cohorts of EGFR/ALK-positive-NSCLC, mutation-negative-NSCLC, and SCLC. Results OS was superior with NSCLC over SCLC in the retrospective dataset (median-OS, 10.5 vs 8.6 months, MV-p Conclusion After SRS, SCLC was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC overall but was similar in patients matched on baseline characteristics. Neurological mortality, lesions at CNS-progression, and leptomeningeal-progression were comparable. These findings may better inform clinical decision-making for SCLC patients.
- Published
- 2023
49. Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy associated with gastric cancer and response to immediate chemotherapy
- Author
-
Kohei Fujita, Takeshi Omori, Hisashi Hara, Naoki Shinno, Masaaki Yamamoto, Takashi Kanemura, Tomohira Takeoka, Takahito Sugase, Hiroshi Miyata, Masayuki Ohue, and Masato Sakon
- Subjects
General Medicine - Published
- 2022
50. ASO Visual Abstract: Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy
- Author
-
Keijiro Sugimura, Hiroshi Miyata, Takashi Kanemura, Tomohira Takeoka, Takahito Sugase, Masaaki Yamamoto, Naoki Shinnno, Hisashi Hara, Takeshi Omori, Masaaki Motoori, Masayuki Ohue, and Masahiko Yano
- Subjects
Oncology ,Surgery - Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.